B7-H3 (CD276) expression
B7-H3 is an immune checkpoint protein overexpressed on small-cell lung, prostate and many solid tumours. Ifinatamab deruxtecan is in phase 3 for small-cell lung cancer without an expression cut-off; nothing is approved.
Overview
Ifinatamab deruxtecan (I-DXd) is being compared with topotecan or other chemotherapy in relapsed small-cell lung cancer in IDeate-Lung02 (NCT06203210) with no B7-H3 selection; earlier phase studies found responses across expression levels. Other B7-H3 ADCs and radioligands are in early trials. No regulator has approved a B7-H3-directed drug.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · B7-H3 is an immune checkpoint-like surface protein found on 60 to 70% of small-cell lung cancers and 80 to 90% of castration-resistant prostate cancers, with little on normal tissue. It is used as an ADC address, chiefly by ifinatamab deruxtecan, now in phase 3 in small-cell lung cancer; whether blocking its immune-dampening role adds anything beyond payload delivery is unresolved.
B7-H3 is a research target. If you have small-cell lung cancer that has returned, a trial of ifinatamab deruxtecan may be open to you without any B7-H3 test; ask your team.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
The label names the antigen in the drug's description but does not require it to be measured before treatment; no approval threshold exists for this readout.
“IDeate-Lung02: ifinatamab deruxtecan versus treatment of physician's choice in relapsed small cell lung cancer”
ClinicalTrials.gov NCT06203210 (IDeate-Lung02)No approval uses this readout as a threshold. It is defined by IDeate-Lung02 (NCT06203210).
Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.
- NCT07189871177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- NCT07099898A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
- NCT06362252A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-
- NCT07502287Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
- NCT07500220Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
- NCT06203210IDeate-Lung02
- NCT05280470Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- NCT07680439Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
Similar pages
not linked directly; found by shared links- BiomarkerBCMA expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerCD38 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerCEACAM5 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerFcRH5 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerGPRC5D expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerHER3 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerNectin-4 expression
Shares the tags biomarker, surface-antigen, no-threshold.
- BiomarkerTissue factor expression
Shares the tags biomarker, surface-antigen, no-threshold.